This April, Amgen started work on therapeutic antibodies targeting SARS-CoV-2. deCODE Genetics, an Amgen subsidiary in Iceland, is providing insights from patient samples on the genomics of the virus and individual patients. In this seminar, Kári Stefánsson, Founder & CEO of deCODE, will summarize what the company has learned about COVID-19. Ray Deshaies, Senior Vice President for Global Research at Amgen, will give us a look at how human “omics” data is providing insights into Amgen’s drug development projects.
Where & When
Thursday, August 20, 2020
Zoom Webinar
About the Speakers
Raymond Deshaies, Ph.D., Senior Vice President, Global Research, Amgen
Raymond Deshaies, Ph.D., is senior vice president, Global Research, at Amgen.
Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute.
In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Biosciences.
Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences.
Kári Stefánsson, M.D., Dr. Med., Founder & CEO, deCODE genetics
Kári Stefánsson, M.D., Dr. Med., founded deCODE in August 1996. Dr. Stefánsson was previously a professor of Neurology, Neuropathology and Neuroscience at Harvard University and Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States. Dr. Stefansson is recognized as a leading figure in human genetics. He has shaped deCODE’s scientific approach and been actively engaged in leading its gene discovery work, serving as senior author on most of the company’s publications in major scientific journals.